Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LYPLA1 | O75608 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128907 | 0.97 | APP (0.46) | APPPTGS1PDE4AALDH1A1TSHR | |
| Water SCHEMBL21226523 | 0.95 | APP (0.44) | APPPTGS1PDE4AALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL3148714 | 0.95 | APP (0.44) | APPPTGS1PDE4AALDH1A1TSHR | |
| Water SCHEMBL30397698 | 0.93 | APP (0.42) | APPPTGS1PDE4AALDH1A1TSHR | |
| Dimethylamine SCHEMBL918206 | 0.91 | APP (0.41) | APPPTGS1PDE4AALDH1A1TSHR | |
| SCHEMBL353885 | 0.90 | ALDH1A1 (0.48) | APPPTGS1PDE4AALDH1A1TSHR | |
| SCHEMBL28560997 | 0.89 | APP (0.39) | APPPTGS1PDE4AALDH1A1TSHR | |
| Sulfuric Acid SCHEMBL29054592 | 0.88 | ALDH1A1 (0.46) | APPPTGS1PDE4AALDH1A1TSHR | |
| SCHEMBL17655619 | 0.88 | ALDH1A1 (0.52) | APPPTGS1PDE4AALDH1A1TSHR | |
| SCHEMBL2923686 | 0.88 | ALDH1A1 (0.52) | APPPTGS1PDE4AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393875-B2 | Reducing islet amyloid polypeptide (IAPP) associated deposit; type II diabetes | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-07-01 | — | — | US | claimed |
| EP-1609467-A1 | Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions | Neurochem (International) Limited (CH) | 2005-12-28 | — | — | EP | claimed |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | QUEEN'S UNIVERSITY | 2002-12-19 | — | — | US | claimed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | claimed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| EP-1609467-A1 | Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions | Neurochem (International) Limited (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040096453-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-05-20 | — | — | US | disclosed |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | QUEEN'S UNIVERSITY | 2002-12-19 | — | — | US | disclosed |
| US-6310073-B1 | ADMINISTERING TO SUBJECT THERAPEUTICALLY EFFECTIVE AMOUNT OF 3-AMINO-1-PROPANESULFONIC ACID, OR PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, SUCH THAT GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTION IS MODULATED AND CONDITION IS TREATED | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-30 | — | — | US | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096453-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | APP 4261/4885PTGS1 944/4885PDE4A 3957/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | APP 4399/4885PTGS1 757/4885PDE4A 3686/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | APP 4261/4885PTGS1 944/4885PDE4A 3957/4885 |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | APP 4399/4885PTGS1 757/4885PDE4A 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.